Cidara Therapeutics, Inc. (NASDAQ:CDTX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders
its 2017 Annual Meeting of Stockholders (the “Annual Meeting”).
As of April 25, 2017, the record date for the Annual Meeting,
16,825,918 shares of the Companys common stock were outstanding
and entitled to vote at the Annual Meeting. A summary of the
matters voted upon by stockholders at the Annual Meeting is set
forth below.
present at the meeting in person or by proxy, which represents
approximately 67% of the shares of common stock outstanding as of
the record date for the Annual Meeting.
Class II Directors, each to serve until the Companys 2020 Annual
Meeting of Stockholders and until their successors are duly
elected and qualified. The final voting results are as follows:
|
Name
|
|
Votes For
|
|
Votes Withheld
|
|
Broker Non-Votes
|
|||
|
Daniel Burgess
|
|
6,471,807
|
|
2,178,917
|
|
2,624,123
|
|||
|
Theodore R. Schroeder
|
|
6,558,222
|
|
2,092,502
|
|
2,624,123
|
Registered Public Accounting Firm
LLP by the Audit Committee of the Companys Board of Directors as
the Companys independent registered public accounting firm for
the fiscal year ending December 31, 2017. The final voting
results are as follows:
|
Votes For
|
Votes Against
|
Abstention
|
Broker Non-Votes
|
||||
|
11,178,714
|
62,716
|
33,417
|
About Cidara Therapeutics, Inc. (NASDAQ:CDTX)
Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease.
